// SECTOR DOSSIER
biotechnology Unicorns
Every biotechnology unicorn we track — 14 private companies valued $1B or more, tiered by paper valuation. Combined balance sheet myth: $88B.
TIER 2 // PRIORITY TARGETS
The Decacorns $10B – $99B · 4
TIER 3 // STANDING HORDE